Ironwood Pharmaceuticals (NASDAQ: IRWD) developed linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation.
Status: Public
Innovent Biologics
Innovent Biologics (1801.HK) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases.
Hua Medicine
Hua Medicine (2552.KHK) is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders.
Hile BioPharma
Hile (603718.SS) is a leading animal vaccine manufacturer that specializes in sales, marketing and commercialization of animal vaccine products in China.
Coherus Biosciences
Coherus Biosciences (NASDAQ: CHRS) is a biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide.
Blueprint Medicines
Blueprint Medicines (NASDAQ: BPMC) is a precision therapy company striving to improve human health. Blueprint Medicines was acquired by Sanofi in 2025.
Adagene
Adagene (Nasdaq: ADAG) is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody.
Aclaris Therapeutics
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology.
Acacia Pharma
Acacia Pharma (EURONEXT: ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Acacia developed BARHEMSYS to marketing approval and was acquired by Eagle Pharmaceuticals in 2022.